La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Beximco Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	15.3yrs
Durata media del Consiglio di amministrazione	3.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Beximco Pharmaceuticals non ha un CEO, o non abbiamo dati su di loro.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Mohammad Nawaz	Chief Financial Officer	15.6yrs	Nessun dato	Nessun dato
S. M. Reza	Chief Operating Officer	15.3yrs	Nessun dato	Nessun dato
Jamal Choudhury	Director of Accounts & Finance	no data	Nessun dato	Nessun dato
Rizvi Kabir	Director of Marketing	no data	Nessun dato	Nessun dato
M. A. Bhuiyan	General Manager of Human Resources	no data	Nessun dato	Nessun dato
Zakaria Chowdhury	Head of Distribution Services & Director of International Marketing	14.6yrs	Nessun dato	Nessun dato
Mohammad Ullah	Company Secretary & Executive Director	no data	Nessun dato	Nessun dato

15.3yrs

Durata media

Gestione esperta: Il team dirigenziale di BXPHARMA è esperto e expertise (durata media dell'incarico 15.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Mohammad Ullah	Company Secretary & Executive Director	no data	Nessun dato	Nessun dato
Salman Rahman	Vice Chairman	no data	Nessun dato	2.04% BDT 680.1m
Abu Bakar Rahman	Director	31.6yrs	Nessun dato	Nessun dato
Osman Chowdhury	Director	no data	Nessun dato	Nessun dato
Iqbal Ahmed	Director	39.6yrs	Nessun dato	Nessun dato
Ahmed Sohail Rahman	Chairman	no data	Nessun dato	2.03% BDT 678.5m
Quamrun Ahmed	Non-Executive Director	3.8yrs	Nessun dato	Nessun dato
Mamtaz Ahmed	Independent Non-Executive Director	4.1yrs	Nessun dato	Nessun dato
Reem Shamsuddoha	Non-Executive Director	3.8yrs	Nessun dato	Nessun dato
Md. Hosein Khan	Independent Director	3.6yrs	Nessun dato	Nessun dato

3.9yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BXPHARMA sono considerati esperti (durata media dell'incarico 3.9 anni).

Beximco Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Managing Director

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Member of the Board

Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023

Less than half of directors are independent

Less than half of directors are independent

Beximco Pharmaceuticals Limited Announces Board Changes

Recent updates

Price target increased by 9.3% to ৳168

Third quarter 2024 earnings released: EPS: ৳3.06 (vs ৳2.13 in 3Q 2023)

Beximco Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 29, 2024

Second quarter 2024 earnings released: EPS: ৳3.21 (vs ৳2.77 in 2Q 2023)

Beximco Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 29, 2024

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Managing Director

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Member of the Board

Upcoming dividend of ৳3.50 per share at 2.4% yield

Full year 2023 earnings released: EPS: ৳10.34 (vs ৳11.48 in FY 2022)

Beximco Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 05, 2023

Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023

Beximco Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Oct 19, 2023

Third quarter 2023 earnings released: EPS: ৳2.13 (vs ৳2.47 in 3Q 2022)

Second quarter 2023 earnings released: EPS: ৳2.77 (vs ৳3.84 in 2Q 2022)

Beximco Pharmaceuticals Limited Announces Cash Dividend for the Year Ended June 30, 2022

Less than half of directors are independent

Full year 2022 earnings: EPS misses analyst expectations

Beximco Pharmaceuticals Limited Proposes Dividend for the Year Ended 30 June 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations

Price target increased to ৳182

Less than half of directors are independent

Now 20% undervalued after recent price drop

Consensus EPS estimates increase by 18%

Second quarter 2022 earnings: EPS exceeds analyst expectations

Beximco Pharmaceuticals Limited Launches First Generic Version of Pfizer's COVID-19 Treatment Paxlovid

Upcoming dividend of ৳3.50 per share

Full year 2021 earnings released: EPS ৳11.49 (vs ৳7.88 in FY 2020)

Third quarter 2021 earnings released: EPS ৳3.28 (vs ৳2.02 in 3Q 2020)

Investor sentiment improved over the past week

Beximco Pharmaceuticals Limited Updates on the Supply of Covid-19 Vaccine

Second quarter 2021 earnings released: EPS ৳2.54 (vs ৳1.93 in 2Q 2020)

Analysts increase EPS estimates to ৳10.32

Price target raised to ৳114

Beximco Pharmaceuticals Limited Announces Board Changes

Beximco Pharmaceuticals Limited Provides Update on the Supply of COVID-19 Vaccine

Beximco Pharmaceuticals Limited Confirms Quamrun Naher Ahmed and Reem H. Shamsuddoha as Non-Executive Directors

Investor sentiment improved over the past week

New 90-day high: ৳170

New 90-day high: ৳159

Beximco Pharmaceuticals Limited Announces Directors Appointments

New 90-day high: ৳148

Price target raised to ৳113

New 90-day high: ৳148

Price target raised to ৳116

New 90-day high: ৳145

First quarter 2021 earnings released: EPS ৳2.65

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS ৳8.67

Beximco Pharmaceuticals Limited Enters into A Memorandum of Understanding for the Supply and Distribution of 30 Million Doses of the Oxford University/AstraZeneca SARS-CoV-2 Vaccine, AZD1222, in Bangladesh

New 90-day high: ৳127

Beximco Pharmaceuticals Limited Receives US Food and Drug Administration (Fda) Approval for Antiarryhtmic Drug Flecainide

Price target raised to ৳105

New 90-day high - ৳116

AMMINISTRATORE DELEGATO

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media